AT204325T - Preparation made of antibodies or functional parts thereof derived from heavy chains of immunoglobulins of camelidae - Google Patents

Preparation made of antibodies or functional parts thereof derived from heavy chains of immunoglobulins of camelidae

Info

Publication number
AT204325T
AT204325T AT94916201T AT94916201T AT204325T AT 204325 T AT204325 T AT 204325T AT 94916201 T AT94916201 T AT 94916201T AT 94916201 T AT94916201 T AT 94916201T AT 204325 T AT204325 T AT 204325T
Authority
AT
Austria
Prior art keywords
camelidae
immunoglobulins
antibodies
derived
heavy chains
Prior art date
Application number
AT94916201T
Other languages
German (de)
Inventor
Raymond Hamers
Cecile Hamers-Casterman
Serge Victor M Muyldermans
Leon Gerardus J Frenken
Cornelis Theodorus Verrips
Original Assignee
Unilever Nv
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP93201239 priority Critical
Priority to EP93201454 priority
Priority to EP93202079 priority
Application filed by Unilever Nv, Univ Bruxelles filed Critical Unilever Nv
Priority to PCT/EP1994/001442 priority patent/WO1994025591A1/en
Publication of AT204325T publication Critical patent/AT204325T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27235299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT204325(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
AT94916201T 1993-04-29 1994-04-28 Preparation made of antibodies or functional parts thereof derived from heavy chains of immunoglobulins of camelidae AT204325T (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP93201239 1993-04-29
EP93201454 1993-05-19
EP93202079 1993-07-15
PCT/EP1994/001442 WO1994025591A1 (en) 1993-04-29 1994-04-28 PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)

Publications (1)

Publication Number Publication Date
AT204325T true AT204325T (en) 2001-09-15

Family

ID=27235299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916201T AT204325T (en) 1993-04-29 1994-04-28 Preparation made of antibodies or functional parts thereof derived from heavy chains of immunoglobulins of camelidae

Country Status (7)

Country Link
US (2) US6838254B1 (en)
AT (1) AT204325T (en)
AU (1) AU6796094A (en)
DE (2) DE69427974T2 (en)
DK (1) DK0698097T3 (en)
ES (1) ES2162863T3 (en)
WO (1) WO1994025591A1 (en)

Families Citing this family (331)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
GB9620093D0 (en) * 1996-09-26 1996-11-13 Unilever Plc Photofading inhibitor derivatives and their use in fabric treatment compositions
EP0988360A2 (en) * 1997-06-13 2000-03-29 Unilever N.V. Bleaching enzymes
US6670453B2 (en) 1997-10-27 2003-12-30 Unilever Patent Holdings B.V. Multivalent antigen-binding proteins
EP0954978B1 (en) 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
AT535154T (en) 1998-03-12 2011-12-15 Vhsquared Ltd Products containing the inactivated mold that have on their outside surface active antibody yeasts or
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU759986B2 (en) * 1998-12-11 2003-05-01 Unilever Plc Bleaching enzymes and detergent compositions comprising them
AU2291700A (en) * 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
CN1252264C (en) 1999-04-22 2006-04-19 荷兰联合利华有限公司 Inhibition of viral infection using monovalent antigen-binding proteins
TR200200194T2 (en) 1999-07-27 2002-05-21 Unilever N.V. Bleaching detergent compositions
EP1118669A3 (en) * 1999-12-17 2001-08-29 Unilever N.V. Production of camelid antibodies in plants
BR0016659A (en) 1999-12-22 2002-09-03 Unilever Nv Method to release a benefit agent to fabric for exerting a predetermined activity, and detergent composition
BR0016657B1 (en) 1999-12-22 2010-12-14 METHOD to release a benefit agent to a selected area of ​​a tissue to exert a predetermined activity, and device for use in the same.
BR0016655B1 (en) 1999-12-22 2011-12-13 method to release a benefit agent.
CA2392158C (en) * 1999-12-22 2011-04-19 Unilever Plc Detergent compositions comprising benefit agents
EP1479694B1 (en) 1999-12-28 2016-10-26 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies ScFv with defined framework that is stable in a reducing environment
AT428733T (en) * 2000-03-14 2009-05-15 Unilever Nv Variabele domains of the heavy chain of an antibody against human ernährungslipasen and their uses
AT352040T (en) 2000-11-17 2007-02-15 Univ Rochester In-vitro method for producing and identifying immunoglobulin molecules in eukaryotic cells
US20040053340A1 (en) * 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
CA2431485A1 (en) 2000-12-19 2002-06-27 Unilever Plc Stabilization of antibodies or fragments thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ES2337986T3 (en) 2001-08-10 2010-05-03 Aberdeen University Antigen binding domains fish.
JP2005289809A (en) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
EP1318195A1 (en) * 2001-12-10 2003-06-11 CatchMabs B.V. A structure for presenting desired peptide sequences
CA2472927A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
WO2003089614A2 (en) * 2002-04-18 2003-10-30 Genencor International, Inc. Production of functional antibodies in filamentous fungi
WO2004006847A2 (en) 2002-07-15 2004-01-22 Board Of Regents, The University Of Texas System Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc Fcgammariib-specific antibodies and procedures for use thereof
AU2003270652A1 (en) * 2002-09-16 2004-04-30 Advanced Bionutrition Corporation Protein and peptide expression for passive immunity
NZ563471A (en) * 2002-11-08 2009-04-30 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
MXPA05006043A (en) 2003-01-10 2006-01-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation.
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US6974860B2 (en) * 2002-12-30 2005-12-13 Kimberly-Clark Worldwide, Inc. Target recognizing binding agents
WO2004069872A1 (en) * 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
ES2408582T3 (en) 2003-05-30 2013-06-21 Merus B.V. Fab library for the preparation of a mixture of antibodies
WO2005014795A2 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
DK1703893T3 (en) 2003-12-23 2012-05-07 Genentech Inc Hitherto UNKNOWN ANTI-IL13 ANTIBODIES AND APPLICATIONS THEREOF
WO2005068622A2 (en) 2004-01-20 2005-07-28 Merus B.V. Mixtures of binding proteins
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
JP2008511286A (en) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド Binding component based on the IgNAR domain of sharks
CN1942203A (en) * 2004-06-04 2007-04-04 金克克国际有限公司 Screening method using antibody heavy chains
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879605B1 (en) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse antibody formats production and immunological applications of these formats
AT473446T (en) 2005-01-14 2010-07-15 Ablynx Nv The method and test devices to distinguish between different forms of diseases and conditions which are characterized by thrombocytopenia and / or by spontaneous interaction between Von Willebrand Factor and platelet
CN103497993A (en) 2005-02-07 2014-01-08 基因信息公司 Mild osteoarthritis biomarkers and uses thereof
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
DE102005023617A1 (en) 2005-05-21 2006-11-23 Aspre Ag A method of mixing colors in a display
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
CA2925307A1 (en) 2005-08-30 2007-03-08 Intrexon Actobiotics Nv Novel treatment of chronic enterocolitis
DK1931710T3 (en) 2005-08-31 2017-04-03 Merck Sharp & Dohme Constructed anti-il-23 antibodies
EP1933869B1 (en) 2005-09-01 2009-10-14 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
JP5237817B2 (en) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド Method and apparatus for correlating biomarker product levels with disease
KR20180002911A (en) 2005-11-04 2018-01-08 제넨테크, 인크. Use of complement pathway inhibitors to treat ocular diseases
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
EP1999147A1 (en) * 2006-03-27 2008-12-10 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2447719B1 (en) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteins
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc Fc riib-specific antibodies and methods of use thereof
ES2643687T3 (en) 2006-08-28 2017-11-23 Kyowa Hakko Kirin Co., Ltd. HLIGHT antagonist-specific human monoclonal antibodies
EA200970250A1 (en) 2006-09-05 2010-02-26 Медарекс, Инк. Antibodies to bone morphogenetic proteins and their receptors and methods of their application
BRPI0718197A2 (en) 2006-10-02 2014-09-30 Medarex Inc Isolated monoclonal antibody or an antigen-binding portion of the same, composition, immunocated, isolated nucleic acid molecule, expression vector, host cell for preparing a circular ancle4 modules cell, and to stimulate mobilization of cd34 + body body cells for peripheral blood in an individual.
CA2980614A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Complement inhibition for improved nerve regeneration
US8173423B2 (en) 2006-11-07 2012-05-08 Vib Vzw Diagnosis and treatment of T-cell acute lymphoblastic leukemia
NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
BRPI0718349A2 (en) 2006-12-13 2014-01-14 Medarex Inc Joint antibody partnership composition, method of inhibition of the growth of a tumor cell expressing cd19, b-cell exhaust method in a subject and method of treatment of a subject to a cancer
JP5059119B2 (en) 2006-12-14 2012-10-24 シェーリング コーポレイションSchering Corporation Engineered anti-TSLP antibody
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
JP2010518858A (en) 2007-02-23 2010-06-03 シェーリング コーポレイションSchering Corporation Engineered anti--il-23p19 antibody
HUE042172T2 (en) 2007-02-23 2019-06-28 Merck Sharp & Dohme Engineered anti-il-23p19 antibodies
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
NZ579297A (en) 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
JP5622397B2 (en) 2007-03-12 2014-11-12 エスバテック− ア ノバルティス カンパニー エルエルシー Single-chain antibody sequence-based manipulation and optimization
WO2008118013A2 (en) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
US20130195881A1 (en) 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
AU2008246442B2 (en) 2007-05-04 2014-07-03 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
NZ599278A (en) 2007-05-14 2013-12-20 Medimmune Llc Methods of reducing eosinophil levels
EA200901646A1 (en) 2007-06-05 2010-08-30 Йел Юниверсити Receptor thyrozinkinase inhibitors and their application
CN101849001B (en) * 2007-06-25 2014-07-16 艾斯巴技术-诺华有限责任公司 Methods of modifying antibodies, and modified antibodies with improved functional properties
US9908945B2 (en) * 2007-06-25 2018-03-06 Esbatech, An Alcon Biomedical Research Unit Llc Sequence based engineering and optimization of single chain antibodies
CA2691940C (en) 2007-07-03 2018-03-06 Joost Alexander Kolkman Methods for providing improved immunoglobulin sequences
EP2188306B1 (en) * 2007-08-10 2016-06-29 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
US8501907B2 (en) * 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
PT2195023T (en) 2007-08-29 2018-06-08 Sanofi Sa Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
CN101918447B (en) 2007-12-14 2014-06-11 布里斯托尔-米尔斯·斯奎布公司 Binding molecules to the human OX40 receptor
EP2594584B1 (en) 2008-01-31 2015-07-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Engineered constant domain molecule of an antibody
EP2247616A2 (en) 2008-03-05 2010-11-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
EP2260058A2 (en) 2008-04-07 2010-12-15 Ablynx N.V. Single variable domains against the notch pathways
RU2531754C2 (en) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Immunotherapeutic agent combined with cd37, and its combination with bifunctional chemotherapeutic agent
JP2011516603A (en) 2008-04-17 2011-05-26 アブリンクス エン.ヴェー. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides containing them
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
WO2010011944A2 (en) 2008-07-25 2010-01-28 Wagner Richard W Protein screeing methods
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CA2745218A1 (en) 2008-12-19 2010-06-24 Schering Corporation Feed supplement for mammalian cell culture and methods of use
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
US20100189919A1 (en) * 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
MX2011009220A (en) 2009-03-05 2011-09-28 Medarex Inc Fully human antibodies specific to cadm1.
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP3323427A1 (en) 2009-03-17 2018-05-23 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
EP2411413B1 (en) 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
ES2574236T3 (en) 2009-04-20 2016-06-16 Oxford Biotherapeutics Ltd Specific antibodies for cadherin-17
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
US9464138B2 (en) 2009-04-30 2016-10-11 Ablynx N.V. Method for the production of domain antibodies
EP2432499A2 (en) 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
AU2010276580A1 (en) 2009-07-31 2012-03-15 Medarex, L.L.C. Fully human antibodies to BTLA
JP6294585B2 (en) 2009-09-03 2018-03-20 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Anti-GITR antibody
US9884117B2 (en) 2009-09-03 2018-02-06 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
WO2011046218A1 (en) * 2009-10-16 2011-04-21 株式会社カネカ Hansenula polymorpha capable of producing antibody, process for production of antibody utilizing same, and antibody produced from same
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
NZ599761A (en) 2009-11-04 2014-04-30 Merck Sharp & Dohme Engineered anti-tslp antibody
WO2011054893A2 (en) 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
DK2954779T3 (en) * 2009-12-10 2019-05-13 Regeneron Pharma Mice that produce heavy chain antibodies
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
WO2011098552A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Methods and compositions for the preparation of aerosols
ES2715279T3 (en) 2012-05-24 2019-06-03 Vib Vzw Individual variable immunoglobulin domains of macrophage mannose receptor to choose as target and obtain in vivo images of macrophages associated with tumors
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
MX2012012927A (en) 2010-05-06 2013-05-01 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies.
CN103038258B (en) 2010-05-06 2017-02-15 诺华股份有限公司 Compositions and methods of use for the treatment of low-density lipoprotein-related protein antibody. 6 (LRP6) of
CN102242094A (en) * 2010-05-14 2011-11-16 浙江大学 Method for improving continuity of alpha galactosidase activity
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
CA2805548A1 (en) 2010-07-02 2012-01-05 Vib Vzw The role of fragile x mental retardation gene and protein in cancer metastasis
GB201012845D0 (en) 2010-07-30 2010-09-15 Vib Vzw Inhibition of dicer function for treatment of cancer
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
CA2809837A1 (en) 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
SG188313A1 (en) 2010-09-09 2013-04-30 Pfizer 4-1bb binding molecules
AU2011299066A1 (en) 2010-09-10 2013-03-21 Apexigen, Inc. Anti-IL-1 beta antibodies and methods of use
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
PL2632946T3 (en) 2010-10-29 2018-06-29 Ablynx N.V. Method for the production of immunoglobulin single variable domains
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
EA028658B1 (en) 2010-12-23 2017-12-29 Янссен Байотек, Инк. MODIFIED PROTEASE-RESISTANT Fc-CONTAINING MOLECULE, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A DISEASE COMPRISING USE THEREOF
EP2658869B1 (en) 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
RU2013144392A (en) 2011-03-03 2015-04-10 Апексиджен, Инк. Antibodies to il-6 receptor and methods of application
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
AU2012234282B2 (en) 2011-03-28 2015-07-16 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
CA2830806A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
RU2609647C2 (en) 2011-04-29 2017-02-02 Апексиджен, Инк. Anti-cd40-antibodies and methods of application
EP2707382B1 (en) 2011-05-09 2019-07-17 Ablynx NV Method for the production of immunoglobulin single variable domains
US9783594B2 (en) 2011-05-17 2017-10-10 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
CA2835340A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
US9580480B2 (en) 2011-05-31 2017-02-28 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
RS55716B1 (en) 2011-06-28 2017-07-31 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AP201407394A0 (en) 2011-06-28 2014-01-31 Oxford Bio Therapeutics Ltd Antibodies to ADP-ribosyl cyclase 2
BR112014002219A2 (en) 2011-07-05 2018-08-07 Bioasis Tech Inc p97 antibody conjugates and methods of use
EP3321281A1 (en) 2011-08-05 2018-05-16 biOasis Technologies Inc P97 fragments with transfer activity
CA2844289A1 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
WO2013041901A1 (en) 2011-09-20 2013-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing single domain antibody microarrays
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
EP2785742A4 (en) 2011-11-02 2016-02-17 Apexigen Inc Anti-kdr antibodies and methods of use
KR20140091031A (en) 2011-11-04 2014-07-18 노파르티스 아게 Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
TW201328706A (en) 2011-12-05 2013-07-16 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
CA2857601A1 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN104080480A (en) 2012-01-01 2014-10-01 奇比艾企业有限公司 Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
MX359854B (en) 2012-01-20 2018-10-12 Genzyme Corp Anti-cxcr3 antibodies.
US20150301068A1 (en) 2012-01-30 2015-10-22 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en) 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
CA2865506A1 (en) 2012-03-15 2013-09-19 Omeros Corporation Composition and method for diversification of target sequences
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
SG11201406770WA (en) 2012-04-20 2014-11-27 Merus B V Methods and means for the production of ig-like molecules
EP2687595B1 (en) * 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme Antibodies that bind to human ligand 1 programmed death (pd-l1)
KR20150100715A (en) 2012-12-21 2015-09-02 앰플리뮨, 인크. Anti-h7cr antibodies
JP6443344B2 (en) 2013-01-30 2018-12-26 フエー・イー・ベー・フエー・ゼツト・ウエー Novel chimeric polypeptides for screening and drug development
JP2016508496A (en) 2013-02-05 2016-03-22 エンクマフ アーゲー Method for the selection of antibodies against BCMA
CA2900147A1 (en) 2013-02-05 2014-08-14 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
CA2902068A1 (en) 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
CA2906003A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
JP6499090B2 (en) 2013-03-15 2019-04-10 ブイアイビー ブイゼットダブリュVib Vzw Anti-macrophage mannose receptor single variable domain for use in cardiovascular disease
MD4633B1 (en) 2013-03-18 2019-06-30 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
WO2014146575A1 (en) 2013-03-19 2014-09-25 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CA2910874A1 (en) 2013-04-29 2014-11-06 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
KR20160129698A (en) 2013-05-24 2016-11-09 메디뮨 엘엘씨 Anti-b7-h5 antibodies and their uses
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
CA2914369A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
KR20170140424A (en) 2013-08-02 2017-12-20 화이자 인코포레이티드 Anti-cxcr4 antibodies and antibody-drug conjugates
ES2650917T3 (en) 2013-08-07 2018-01-23 Alexion Pharmaceuticals, Inc. biomarker proteins of atypical hemolytic uremic syndrome (SUHA)
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulation of tumor immunity
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP3083693A2 (en) 2013-12-20 2016-10-26 Intervet International B.V. Antagonistic anti-canine pd-1 antibodies
WO2015121092A1 (en) 2014-01-30 2015-08-20 Vib Vzw Opioid receptor binding agents and uses thereof
JP2017512458A (en) 2014-02-05 2017-05-25 モレキュラー テンプレーツ,インク.Molecular Templates, Inc. Methods for screening, selecting and identifying cytotoxic recombinant polypeptides based on a temporary reduction in ribotoxicity
AU2015219339A1 (en) 2014-02-19 2016-07-07 Bioasis Technologies, Inc. P97-IDS fusion proteins
MX2017011194A (en) 2015-03-03 2018-04-10 Kymab Ltd Antibodies, uses & methods.
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
AU2015252906A1 (en) 2014-05-01 2016-10-06 Bioasis Technologies, Inc. p97-polynucleotide conjugates
JP2017526615A (en) 2014-05-28 2017-09-14 アジェナス インコーポレイテッド Anti-GITR antibody and method of use thereof
PL3149172T3 (en) 2014-05-29 2018-10-31 Quark Pharmaceuticals, Inc. Methods and compositions for preventing ischemia reperfusion injury in organs
SG11201610170SA (en) 2014-06-06 2017-01-27 Bluebird Bio Inc Improved t cell compositions
US9855348B2 (en) 2014-07-29 2018-01-02 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
CN107001470A (en) 2014-08-19 2017-08-01 默沙东公司 Anti-LAG3 antibodies and antigen-binding fragments
TN2017000024A1 (en) 2014-08-19 2018-07-04 Merck Sharp & Dohme Anti-tigit antibodies.
JP2018502050A (en) 2014-10-09 2018-01-25 エンクマフ アーゲー Bispecific antibodies against CD3ε and ROR1
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2016071438A2 (en) 2014-11-05 2016-05-12 Agrosavfe Nv Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
SG11201704727WA (en) 2014-12-12 2017-07-28 Bluebird Bio Inc Bcma chimeric antigen receptors
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
JP2018504383A (en) 2014-12-19 2018-02-15 アブリンクス エン.ヴェー. Cysteine-linked nanobody dimer
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US20180112008A1 (en) 2015-03-17 2018-04-26 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
US20180087087A1 (en) 2015-03-25 2018-03-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
US20180074077A1 (en) 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
BR112017020275A2 (en) 2015-03-31 2018-06-05 Vhsquared Ltd polypeptides
JP2018511322A (en) 2015-04-02 2018-04-26 インターベット インターナショナル ベー. フェー. Antibodies against canine interleukin 4 receptor alpha
US20180105603A1 (en) 2015-04-13 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
JP6432942B2 (en) * 2015-06-23 2018-12-05 日立オートモティブシステムズ株式会社 Brake device
CA2993432A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
CN105132452A (en) * 2015-09-07 2015-12-09 复旦大学 Recombinant vector for expressing histidine-tag-fused foreign gene in Kluyveromyces marxianus nutritional deficient strain
CN105063082A (en) * 2015-09-07 2015-11-18 复旦大学 Recombinant vector used for carrying out foreign gene secretory expression in auxotrophic kluyveromyces marxianus strain
MX2018003533A (en) 2015-09-24 2019-04-25 Abvitro Llc Hiv antibody compositions and methods of use.
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
US20190040140A1 (en) 2016-03-24 2019-02-07 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
WO2017182603A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
TW201815826A (en) 2016-08-03 2018-05-01 美商爾察禎有限公司 PLAZOMICIN antibodies and methods of use
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
AU2017343621A1 (en) 2016-10-11 2019-04-11 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US20190276524A1 (en) 2016-10-12 2019-09-12 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
US20190242893A1 (en) 2016-10-19 2019-08-08 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
EP3529618A1 (en) 2016-10-19 2019-08-28 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
WO2018081400A1 (en) 2016-10-27 2018-05-03 Alexion Pharmaceuticals Inc. Assay for c5b-9 deposition in complement-associated disorders
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
CN110167964A (en) 2016-11-02 2019-08-23 英格玛布有限责任公司 Combine the bispecific antibody and immune drug for BCMA and CD3 for treating Huppert's disease
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20190080934A (en) 2016-11-16 2019-07-08 아블린쓰 엔.브이. CD123 and T cell mobilization polypeptides capable of binding to TCR alpha / beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US20180155422A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
CA3046205A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
CA3054623A1 (en) 2017-02-28 2018-09-07 Vib Vzw Means and methods for oral protein delivery
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
TW201841942A (en) 2017-04-13 2018-12-01 美商艾吉納斯公司 Anti-CD137 antibodies and methods of use thereof
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
WO2018192974A1 (en) 2017-04-18 2018-10-25 Université Libre de Bruxelles Biomarkers and targets for proliferative diseases
WO2018195034A1 (en) 2017-04-19 2018-10-25 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018201096A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
TW201843178A (en) 2017-05-01 2018-12-16 美商艾吉納斯公司 Anti-TIGIT antibodies and methods of use thereof
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
TW201900191A (en) 2017-05-12 2019-01-01 美國西奈山伊坎醫學院 Newcastle disease virus and its use
TW201920287A (en) 2017-06-02 2019-06-01 德商麥克專利有限公司 ADAMTS binding immunoglobulins
WO2018220235A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
WO2018220236A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
TW201902930A (en) 2017-06-02 2019-01-16 比利時商艾伯林克斯公司 Aggrecan binding of immunoglobulin
EP3415010A1 (en) 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Dhodh inhibitor and chk1 inhibitor for treating cancer
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology Multiple specificity binders of cxc chemokines and uses thereof
WO2019051164A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
WO2019110693A1 (en) 2017-12-05 2019-06-13 Celyad S.A. Compositions and methods for improving persistence of cells for adoptive transfer
WO2019110667A1 (en) 2017-12-05 2019-06-13 Celyad S.A. Reducing fratricide of immune cells expressing nkg2d-based receptors
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
WO2019157191A1 (en) 2018-02-07 2019-08-15 Georgia Tech Research Corporation Methods for multiplexed cell isolation using dna gates
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019180204A1 (en) 2018-03-23 2019-09-26 Université Libre de Bruxelles Wnt signaling agonist molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL82935D0 (en) 1986-08-12 1987-12-20 Phillips Petroleum Co Secretion of heterologous proteins from yeast
DE68921364D1 (en) 1988-04-16 1995-04-06 Celltech Ltd A process for the production of proteins by recombinant DNA.
GB8927230D0 (en) 1989-12-01 1990-01-31 Unilever Plc Reagents
FI913434A (en) 1990-07-16 1992-01-17 Technical Research Centre F Finland Rekombinanta fusionsproteiner Vilka utsoendras.
EP0584421A1 (en) 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT656946E (en) 1992-08-21 2001-12-28 Univ Bruxelles Immunoglobulins for light chains
AT285472T (en) * 1992-08-28 2005-01-15 Novo Nordisk As glucagon

Also Published As

Publication number Publication date
ES2162863T3 (en) 2002-01-16
DE69427974D1 (en) 2001-09-20
DK0698097T3 (en) 2001-10-08
WO1994025591A1 (en) 1994-11-10
DK698097T3 (en)
DE69427974T2 (en) 2001-12-06
AU6796094A (en) 1994-11-21
US6838254B1 (en) 2005-01-04
US20050130266A1 (en) 2005-06-16
US7794981B2 (en) 2010-09-14

Similar Documents

Publication Publication Date Title
DE69006347D1 (en) Colored cosmetic products.
DE69419877T2 (en) Fixed vascular prosthesis
DE69419804T2 (en) Fixed vascular prosthesis
DE69130607D1 (en) Modification of polymer surfaces
DE69033857D1 (en) humanized antibodies
DE3860595D1 (en) One-piece snap hinge closure.
DE69104618T2 (en) Tamper-evident band.
DE69023900D1 (en) Genetically engineered immunoglobulins.
DE69114830T2 (en) Whiz.
AT531812T (en) Humanization of rodent antibodies
AT111714T (en) Production of prostheses.
DE69431495D1 (en) Adaptive, matched filter
FI20070170A (en) Immunoglobulins, which lack light chains
AT234193T (en) The manufacture of composite structures
DE59106063D1 (en) Tibial intramedullary nail with adapted cross-section.
DE69726285D1 (en) Isolation of immunoglobulins
DE68925536D1 (en) Humanized immunoglobulins, their preparation and use
DE69017025D1 (en) Niederschlagpolymerisierung of vinyllaktamterpolymeren.
DE69001491T2 (en) Closure.
DE69106618D1 (en) Shampoo composition.
DE447349T1 (en) Forms of composite structures.
DE68909441T2 (en) Modified antibodies.
FI962070A (en) Diaminocyclobutene-3,4-diones as smooth muscle relaxants
DE69020581T4 (en) Improvement of material properties.
NL300238I2 (en) Humanized antibodies against VLA-4 leukocytenadhesiemolecule

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification